Q2 2024 Fulcrum Therapeutics Inc Earnings Call Transcript
Key Points
- Fulcrum Therapeutics Inc (FULC) is on track to report top-line data for the Phase 3 REACH trial of losmapimod by the end of October, ahead of previous guidance.
- The collaboration with Sanofi for the development and commercialization of losmapimod outside the US is progressing well, with an $80 million upfront payment received.
- A high percentage (98%) of patients from the REACH trial opted to enroll in the open-label extension, indicating strong patient interest and potential efficacy.
- Fulcrum's cash position is strong, with $273.8 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2027.
- The company is preparing for the potential NDA filing and US commercial launch of losmapimod, indicating readiness for market entry.
- The Phase 1b PIONEER trial for pociredir is experiencing delays due to long site activation lead times and narrow inclusion-exclusion criteria.
- Fulcrum expects to remain in a loss position for the foreseeable future, excluding potential milestone payments from the Sanofi collaboration.
- There are no approved therapies for FSHD, and the success of losmapimod is crucial for addressing this unmet need.
- The company faces challenges in establishing the value proposition for losmapimod with payers, particularly regarding genetic testing requirements.
- The clinical trial for pociredir is taking longer than expected, with data not anticipated until 2025, delaying potential advancements in sickle cell disease treatment.
Good morning and welcome to Fulcrum's Therapeutics second quarter 2024 financial results and business update conference call. (Operator Instructions). This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com, and is being recorded.
Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These may include statements about the company's future expectations and plans, clinical development timelines and financial projections. While these forward-looking statements represent Fulcrum's view as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future but is not taking on an obligation to do so.
Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
